MEDIAN TECHNOLOGIES (EPA:ALMDT) | Finanzwire

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Home
Companies
MEDIAN TECHNOLOGIES

BRIEF

published on 05/16/2025 at 17:50, 6 months 19 days ago

Median Technologies Announces Voting Rights and Share Capital Details

Share Capital Voting Rights Treasury Shares AMF Regulations Median Technologies
PRESS RELEASE

published on 05/16/2025 at 17:45, 6 months 19 days ago

Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Median Technologies discloses total voting rights and shares as of April 30, 2025, in compliance with regulations. The French company utilizes AI for cancer diagnosis and treatment

Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF

published on 03/14/2025 at 17:50, 8 months 21 days ago

Median Technologies Maintains its Eligibility for the PEA-PME Scheme

PEA-PME Euronext Growth Tax Benefits Eligibility Median Technologies
BRIEF

published on 02/24/2025 at 17:50, 9 months 8 days ago

Median Technologies: Presentation of eyonis™ LCS at ECR 2025

Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS ECR 2025
BRIEF

published on 01/31/2025 at 08:05, 10 months 4 days ago

Median Technologies unveils its 2024 financial results and its 2025 outlook

Financial Results FDA Approval Median Technologies Eyonis™ LCS Expansion 2025
PRESS RELEASE

published on 01/31/2025 at 08:00, 10 months 4 days ago

Inside Information / Other news releases
Median Technologies reports 2024 financial indicators and 2025 outlook, including eyonis™ LCS FDA clearance and iCRO revenue growth. Strategic milestones and new financing agreements drive towards 2025 goals

Financial Indicators Median Technologies Eyonis LCS 2025 Outlook ICRO Revenue Growth
BRIEF

published on 01/24/2025 at 08:05, 10 months 11 days ago

Median Technologies Secures Up to €47.5 Million for AI Lung Cancer Diagnostics

European Investment Bank Median Technologies AI Lung Cancer Diagnostics Eyonis™ EU And US Commercialization
PRESS RELEASE

published on 01/24/2025 at 08:00, 10 months 11 days ago

Inside Information / Other news releases
Median Technologies secures up to €47.5 million for eyonis™ AI lung cancer diagnostic regulatory filings & U.S./EU commercialization. New financing & operational enhancements drive profitability & extend cash runway into Q4, 2025

AI Commercialization Median Technologies Lung Cancer Diagnostic Eyonis
BRIEF

published on 11/26/2024 at 17:50, 1 year ago

Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024

Clinical Trials Eyonis™ LCS RSNA 2024 AI-powered Diagnostics Lung Cancer Screening
PRESS RELEASE

published on 11/26/2024 at 17:45, 1 year ago

Inside Information / Other news releases
Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at RSNA 2024. Company presents latest developments and REALITY study results to experts in medical imaging conference

AI-powered Median Technologies Eyonis LCS RSNA 2024 Lung Cancer Diagnostic

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 53 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 58 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 28 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 23 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 28 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 27 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 37 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 12 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:00, 13 hours 28 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 43 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE